Mankind Pharma Inks Deal for Two Insulin Analogues The Story: Mankind Pharma has entered an exclusive agreement with Chongqing Chenan to commercialize Insulin Degludec and Insulin Degludec + Aspart in...
Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
